Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
172
resultados
Última actualización
10/10/2025 [06:48:00]
Resultados 75 a 100 de 172
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: CN120267829A
The invention provides an application of a substance for up-regulating the expression level of at least one biomarker in a signal channel of a protease activated receptor 2 (PAR2)-mediated lysosome function in preparation of a composition for one or more of the following: (1) regulating lysosome acidification in a cell; (2) regulating the autophagy function in the cells; (3) regulating autophagosome-lysosome fusion in the cells; (4) the accumulation of reactive oxygen species (ROS) in cells is reduced; (5) reducing the DNA damage level in the cells; (6) reducing the expression level of inflammatory factors in cells; (7) improving or treating acute injury of colitis in the subject; (8) improving or treating the inflammatory bowel disease of the subject; (9) preventing, ameliorating or treating inflammatory cancer transformation in a subject; and (10) preventing, ameliorating or treating colorectal cancer in the subject; wherein the biomarker is selected from PAR2 (Protein Activated Receptor 2), FOXA2 (Forkhead Frame Protein A2) and a lysosome V-type proton pump subunit ATP6V0E1.
Resumen de: CN120254281A
The invention relates to application of an intestinal mucosa inflammation serum marker in preparation of a diagnosis and treatment product for treating the intestinal mucosa inflammation state of a patient suffering from Crohn disease and predicting the treatment effect of infliximab, and belongs to the technical field of biological medicine, and the intestinal mucosa inflammation serum marker is matrix remodeling related 5 protein (MXRA5). When the matrix remodeling related 5 protein (MXRA5) is used as a target spot for serum protein detection, high sensitivity and specificity are achieved, and therefore the MXRA5 protein can be used as a screening target spot for predicting the intestinal mucosa inflammation state of a patient suffering from the Crohn disease and the treatment effect of the infliximab.
Resumen de: CN120254292A
The invention provides a marker combination for predicting recurrence of ulcerative colitis and application thereof, and particularly, the marker is at least one of SLC6A14, MUC-2 and Nanncy index. The marker can be used for diagnosis and recurrence prediction of ulcerative colitis, and especially has relatively strong detection capability for relieving and recurrence conditions of patients after clinical drug treatment.
Resumen de: CN120254102A
The invention provides a quality control method of an effective component of alhagi sparsifolia for treating ulcerative colitis and application of the quality control method, and the method comprises the following steps: characterizing the material composition of the effective component of alhagi sparsifolia by using an ultra-high performance liquid chromatography-mass spectrometry technology, and determining key active components by combining network pharmacology prediction and topological analysis; the quality internal control method for the effective components of the alhagi sparsifolia for treating the ulcerative colitis is constructed by adopting a high performance liquid chromatography technology and a thin-layer chromatography technology, the material information of the effective components of the alhagi sparsifolia can be comprehensively reflected, the quality of the effective components of the alhagi sparsifolia in different batches can be effectively monitored, and the method is high in precision, good in reproducibility and suitable for industrial production. The method can be used for controlling the quality of the effective components of the alhagi sparsifolia for treating ulcerative colitis, and provides a basis for solving the problem that the existing standard cannot comprehensively and systematically analyze the material composition and content control of the effective components of the alhagi sparsifolia.
Resumen de: CN120249471A
The invention relates to the field of biological medicine, and particularly provides application of a membrane protein CMTM3 as a drug target for treating inflammatory bowel disease and related colorectal cancer. The invention discovers and verifies that deletion of Cmtm3 can protect mice from AOM/DSS induced colorectal cancer (CAC) for the first time. A further research result proves that the endothelial cell-derived CMTM3 promotes the development of enteritis. The Cmtm3 gene knockout and the imatinimex can regulate the vascular permeability in a targeted manner and have a considerable curative effect. The application also discloses that the CMTM3 promotes vascular permeability to aggravate enteritis by stabilizing CLTC and increasing gridding protein mediated endocytosis of VE-cadherin in endothelial cells, thereby promoting the development of inflammation-related colon cancer, which indicates that the CMTM3 can be used as a potential therapeutic target for enteritis and colon cancer (CAC).
Resumen de: WO2025141157A1
The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (AI) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the AI is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC- features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.
Resumen de: US2025213709A1
The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.
Resumen de: EP4578401A1
The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (Al) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the Al is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC-features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: US2024075102A1
Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.
Resumen de: CN120210101A
The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.
Resumen de: CN120214122A
The invention provides application of alpha-ZAL in screening the risk of Crohn disease, and belongs to the technical field of biochemical detection. According to the present invention, the endocrine disrupter alpha-zeenol is adopted as the marker for screening the risk of the Crohn disease, the high performance liquid chromatography-tandem mass spectrometry detection technology is adopted to detect the endocrine disrupter, and the endocrine disrupter is prepared into the kit for the risk analysis of the Crohn disease.
Resumen de: WO2025136105A1
The invention relates to methods of predicting a response of an individual suffering from an inflammatory bowel diseases, such as Crohn's disease (CD) to treatment with a Tumor Necrosis Factor alpha inhibitor (TNFα-i). The invention further relates to anti-TNFα therapy, for treating an individual who was predicted to positively respond to said therapy by the methods of the invention, and to an integrin α4β7 blocking agent, or interleukin (IL)-12 and IL-23 blocking agent, for treating an individual who was predicted not to respond to anti-TNFα therapy by the methods of the invention.
Resumen de: CN120198599A
The invention relates to an intelligent endoscope image evaluation method for ulcerative colitis, and the method comprises the steps: synchronously collecting video streams and three-dimensional point cloud data of a colonic mucosa through an endoscope system equipped with a structured light depth sensor, and constructing a three-dimensional coordinate system based on a colon anatomy trend; based on the three-dimensional point cloud data, constructing a complex topological structure on the surface of the colonic mucosa, and calculating a continuous homology feature set of the lesion area; and based on the persistent homology feature set, constructing a multi-scale graph neural network model of ulcerative colitis and Crohn disease specificity. By implementing the scheme, the structural and topological modeling of the colon mucosa lesion area can be realized, and the morphological characteristic difference between ulcerative colitis and Crohn's disease can be effectively captured. The multi-scale graph neural network fuses macroanatomical segmentation and micropathology features, efficient distinguishing of continuous and jumping lesions is achieved, finally, an intelligent and visual endoscope evaluation report is generated, and the accuracy and real-time performance of auxiliary diagnosis in an operation are improved.
Resumen de: CN120195385A
The invention belongs to the technical field of biomedicine, and particularly relates to application of xylulose-5-phosphoric acid as an inflammatory bowel disease biomarker with intestinal fibrosis characteristics. It is found for the first time that xylulose-5-phosphoric acid is remarkably increased in a biological sample of a patient with the inflammatory bowel disease with the intestinal fibrosis characteristic, and the expression level of xylulose-5-phosphoric acid in the biological sample of the patient with the inflammatory bowel disease with the intestinal fibrosis characteristic is in a positive correlation relation with the occurrence degree of the intestinal fibrosis. The discovery provides an important therapeutic target for predicting or evaluating whether a subject suffers from the inflammatory bowel disease with the intestinal fibrosis characteristic by using the xylulose-5-phosphoric acid as the inflammatory bowel disease biomarker with the intestinal fibrosis characteristic.
Resumen de: CN120174078A
The invention provides a composition for diagnosing Crohn's disease, a kit and application of an enhancer RNA44345 in preparation of the composition, and relates to the technical field of biological medicines. The invention relates to an application of an enhancer RNA44345 in preparation of a composition for diagnosing Crohn's disease, and the enhancer RNA44345 is used as a detection marker of the composition for diagnosing Crohn's disease. The enhancer RNA44345 serves as a detection marker of the composition for diagnosing the Crohn disease, the sensitivity is 74.6%, the specificity is 81.7%, the sensitivity and the specificity are high, and a new tool can be provided for early diagnosis and prognosis evaluation of the Crohn disease.
Resumen de: US2025197388A1
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient: Also provided are dosage units comprising one or more of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or the pharmaceutical compositions described herein, methods of treating an inflammatory bowel disease in a subject in need thereof, or methods of modulating an inflammatory bowel disease marker in a subject in need thereof.
Resumen de: WO2025128818A1
Aspects of the disclosure provides composition and methods for treating a subject having inflammatory bowel disease, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Resumen de: NZ730490A
Described herein are methods and systems for distinguishing diarrhea predominant irritable bowel syndrome (D-IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-vinculin antibodies and anti-CdtB antibodies to distinguish IBS from IBD and celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Resumen de: CN120164631A
The invention discloses a follow-up visit management system for an inflammatory bowel disease patient, and relates to the technical field of medical management. Comprising a patient management module which is in dynamic butt joint with a hospital information system, synchronizes patient data and endoscopic examination results in real time through an HL7 protocol, and establishes an electronic file containing an inflammatory bowel disease specificity tag; the diagnosis and treatment result module is used for storing structured data with temporal markers, including medication time sequences recorded by three groups of timestamps, administration routes and drug categories, auxiliary examination results accompanied with digestive tract pathological section images and hidden space feature vectors extracted from the images through a convolutional neural network; and the diet module is used for carrying out multi-level classification on diet photos uploaded by the patient through an image recognition unit based on MobileNetV3, and outputting food types and intake estimated values. According to the invention, by integrating the multi-dimensional data of the patient, the disease development trend is predicted, and personalized follow-up visit management is provided.
Resumen de: JP2025090706A
To solve the problem in which an inflammatory bowel disease (IBD) can be an existential threat to animals; protein losing enteropathy associated with IBD results in the loss of endogenous hemostatic albumin and immunoglobins through a degraded gut barrier; it is therefore desirable to provide a pet food composition which may beneficially affect animals suffering from IBD, such as by increasing the circulating protein of the animal, increasing biomarkers associated with health, and/or modifying the gut microbiome.SOLUTION: There are provided pet food compositions comprising: about 7 wt.% or more, based on the total weight of the pet food composition, of an amino acid component comprising, lysine, betaine, and a glutamic acid and/or a salt of them; and about 3.3 wt.% or more, based on the total weight of the pet food composition, of a fatty acid component comprising a fatty acid having an aliphatic tail of 6 to 12 carbon atoms and/or an omega-3 fatty acid.SELECTED DRAWING: Figure 1A
Resumen de: WO2025121789A1
The present invention relates to an inflammatory bowel disease model derived from induced pluripotent stem cells and a method for producing same. The inflammatory bowel disease model simulates stable intestinal epithelial cells from induced pluripotent stem cells and remarkably exhibits the expression of inflammation-related genes according to the occurrence and improvement of inflammatory bowel disease, and thus can be effectively used for evaluating the efficacy of a drug for treating inflammatory bowel disease.
Resumen de: CN120142669A
The invention discloses a serum protein and metabolism marker for diagnosis or auxiliary diagnosis of colorectal cancer or ulcerative colitis, the serum protein and metabolism marker comprises 10 serum protein markers or/and 11 serum metabolites, the serum protein markers comprise APOA4, APOC3, APOF, C4B, CLEC3B, FERMT3, NID2, RAB11B, CRP and CSF1, and the serum metabolism markers comprise LysoPA 18: 2, LysoPA 18: 3, Valproic acid, LysoPA 16: 0, Cis-4-DGTS 12: 0, Choline, Acylcarnitine 19: 3 and Cis-4-. By screening differentially expressed serum proteins and metabolites of patients with colorectal cancer and ulcerative colitis, machine learning is utilized to screen markers and construct a diagnosis model, so that diagnosis and auxiliary diagnosis of colorectal cancer are facilitated. In addition, the invention further discloses application of the serum protein and the metabolic marker, and the serum protein marker and the serum metabolic marker are used independently or in a combined mode.
Nº publicación: CN120138119A 13/06/2025
Solicitante:
HAINAN UNIV
\u6D77\u5357\u5927\u5B66
Resumen de: CN120138119A
The invention provides a method for evaluating the intervention effect of probiotics based on baseline intestinal microbiome robustness, which comprises the following steps: collecting a sample of a mouse colitis model for metagenome sequencing, analyzing the robustness of the intestinal microbiome of an individual in a baseline period, and evaluating the intervention effect of the probiotics, the mouse colitis model comprises a control group, a model group and a probiotic group. Experimental results show that based on the robustness of the host baseline microbiome, the curative effect of the probiotic intervention treatment on the IBD can be more accurately deduced. The prediction effect of the robustness of the intestinal microorganisms in the baseline period on probiotic treatment is elaborated, and a theoretical basis and technical support are provided for optimizing a probiotic treatment scheme in clinical practice.
BOPI
Sede Electrónica
